Login Register Cart 0
Generic placeholder image

Recent Patents on Biotechnology

Editor-in-Chief

ISSN (Print): 1872-2083
ISSN (Online): 2212-4012

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Effect of Captopril and BQ123 Endothelin-1 Antagonist on Experimentally Induced Hyperlipidemic Nephropathy in Rats

Author(s): Astha Jaiswal, Bhupesh Chandra Semwal* and Sonia Singh

Volume 17, Issue 2, 2023

Published on: 07 September, 2022

Page: [151 - 162] Pages: 12

DOI: 10.2174/1872208316666220629150347

Price: $65

Abstract

Background: Kidney disease is a universal public health problem, and epidemiological studies demonstrated that the incidences of chronic kidney disease are increasing day by day. However, the efficiency of currently available drugs on the progression of nephropathy is limited. Therefore, the current research was designed to evaluate the therapeutic efficacy of captopril and BQ123 against hyperlipidemia-induced nephropathy in rats.

Objective: The objective of this study was to examine the implication of Endothelin-1 in experimentally induced hyperlipidemic nephropathy in rats.

Methods: Animals were divided into various groups, and the administration of a high-fat diet for six weeks induced hyperlipidemia. After confirmation of hyperlipidemia, treatment was started for the next 14 days. At the end of the experimental period, the animals were sacrificed, and various biochemical parameters and histopathological studies were performed.

Results: Treatment of both the agents in combination effectively decreased BUN levels, serum creatinine, serum nitrite, and proinflammatory markers and ameliorated the pathological injuries to kidneys.

Conclusion: Furthermore, both treatments also inhibited oxidative stress and restored the hyperlipidemia-induced reduction in the level of antioxidant enzymes.

Keywords: Hyperlipidemia, captopril, BQ123, oxidative stress, nephropathy, kidney disease.

« Previous Next »
Graphical Abstract

[1]
Crews DC, Bello AK, Saadi G. Burden, access, and disparities in kidney disease. Braz J Med Biol Res 2019; 52(3): e8338.
[http://dx.doi.org/10.1590/1414-431x20198338] [PMID: 30916222]
[2]
Hoerger TJ, Simpson SA, Yarnoff BO, et al. The future burden of CKD in the United States: A simulation model for the CDC CKD initiative. Am J Kidney Dis 2015; 65(3): 403-11.
[http://dx.doi.org/10.1053/j.ajkd.2014.09.023] [PMID: 25468386]
[3]
Yuan C, Lai CW, Chan LW, Chow M, Law HK, Ying M. Cumulative effects of hypertension, dyslipidemia, and chronic kidney disease on carotid atherosclerosis in Chinese patients with type 2 diabetes mellitus. J Diab Res 2014.
[4]
Chen Q, Zhang Y, Ding D, et al. Estimated glomerular filtration rate and mortality among patients with coronary heart disease. PLoS One 2016; 11(8): e0161599.
[http://dx.doi.org/10.1371/journal.pone.0161599] [PMID: 27537335]
[5]
Li XQ, Zheng X, Chen M, Zhao MH. Characteristics of diabetic nephropathy patients without diabetic retinopathy: A retrospective observational study. Medicine 2017; 96(18): e6805.
[http://dx.doi.org/10.1097/MD.0000000000006805] [PMID: 28471980]
[6]
Bulbul MC, Dagel T, Afsar B, et al. Disorders of lipid metabolism in chronic kidney disease. Blood Purif 2018; 46(2): 144-52.
[http://dx.doi.org/10.1159/000488816] [PMID: 29705798]
[7]
Sun Y, Ge X, Li X, et al. High-fat diet promotes renal injury by inducing oxidative stress and mitochondrial dysfunction. Cell Death Dis 2020; 11(10): 914.
[http://dx.doi.org/10.1038/s41419-020-03122-4] [PMID: 33099578]
[8]
Anguiano L, Riera M, Pascual J, Soler MJ. Endothelin blockade in diabetic kidney disease. J Clin Med 2015; 4(6): 1171-92.
[http://dx.doi.org/10.3390/jcm4061171] [PMID: 26239552]
[9]
Pichler R, Afkarian M, Dieter BP, Tuttle KR. Immunity and inflammation in diabetic kidney disease: Translating mechanisms to biomarkers and treatment targets. Am J Physiol Renal Physiol 2017; 312(4): F716-31.
[http://dx.doi.org/10.1152/ajprenal.00314.2016] [PMID: 27558558]
[10]
Chiarelli F, Gaspari S, Marcovecchio ML. Role of growth factors in diabetic kidney disease. Horm Metab Res 2009; 41(8): 585-93.
[http://dx.doi.org/10.1055/s-0029-1220752] [PMID: 19452424]
[11]
Balakumar P, Chakkarwar VA, Kumar V, Jain A, Reddy J, Singh M. Experimental models for nephropathy. J Renin Angiotensin Aldosterone Syst 2008; 9(4): 189-95.
[http://dx.doi.org/10.1177/1470320308098343] [PMID: 19126658]
[12]
Golomb BA, Evans MA. Statin adverse effects: A review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008; 8(6): 373-418.
[http://dx.doi.org/10.2165/0129784-200808060-00004] [PMID: 19159124]
[13]
Ward NC, Watts GF, Eckel RH. Statin toxicity. Circ Res 2019; 124(2): 328-50.
[http://dx.doi.org/10.1161/CIRCRESAHA.118.312782] [PMID: 30653440]
[14]
Feingold KR. Cholesterol lowering drugs. In: Endotext. Feingold KR, Anawalt B, Boyce A, et al. South Dartmouth (MA): MDText.com, Inc. 2000. Available from: https://www.ncbi.nlm.nih.gov/books/NBK395573/
[15]
Moon JY. Recent update of renin-angiotensin-aldosterone system in the pathogenesis of hypertension. Electrolyte Blood Press 2013; 11(2): 41-5.
[http://dx.doi.org/10.5049/EBP.2013.11.2.41] [PMID: 24627703]
[16]
Srivastava T, Hariharan S, Alon US, et al. Hyperfiltration-mediated injury in the remaining kidney of a transplant donor. Transplantation 2018; 102(10): 1624-35.
[http://dx.doi.org/10.1097/TP.0000000000002304] [PMID: 29847501]
[17]
Li XC, Zhuo JL. Recent updates on the proximal tubule renin-angiotensin system in angiotensin II-dependent hypertension. Curr Hypertens Rep 2016; 18(8): 1-5.
[PMID: 27909229]
[18]
Nishiyama SK, Zhao J, Wray DW, Richardson RS. Vascular function and endothelin-1: Tipping the balance between vasodilation and vasoconstriction. J Appl Physiol 2017; 122(2): 354-60.
[http://dx.doi.org/10.1152/japplphysiol.00772.2016] [PMID: 27909229]
[19]
Wang C, Salahudeen AK, McClain M, Whitehead J. Lipid peroxidation accompanies cyclosporine nephrotoxicity: Effects of vitamin E. Kidney Int 1995; 47(3): 927-34.
[http://dx.doi.org/10.1038/ki.1995.138] [PMID: 7752594]
[20]
Lynch IJ, Welch AK, Kohan DE, Cain BD, Wingo CS. Endothelin-1 inhibits sodium reabsorption by ET(A) and ET(B) receptors in the mouse cortical collecting duct. Am J Physiol Renal Physiol 2013; 305(4): F568-73.
[http://dx.doi.org/10.1152/ajprenal.00613.2012] [PMID: 23698114]
[21]
Helmy MM, Helmy MW, Abd Allah DM, Abo Zaid AM, Mohy El-Din MM. Selective ETA receptor blockade protects against cisplatin-induced acute renal failure in male rats. Eur J Pharmacol 2014; 730: 133-9.
[http://dx.doi.org/10.1016/j.ejphar.2014.03.002] [PMID: 24632086]
[22]
Ahmad N, Veerapalli H, Lankala CR, et al. Endothelin receptor antagonists as a potential treatment of diabetic nephropathy: A systematic review. Cureus 2021; 13(11): e19325.
[http://dx.doi.org/10.7759/cureus.19325] [PMID: 34909290]
[23]
Dhaun N, Macintyre IM, Melville V, et al. Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease. Hypertension 2009; 54(1): 113-9.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.109.132670] [PMID: 19506099]
[24]
Gan Z, Huang D, Jiang J, Li Y, Li H, Ke Y. Captopril alleviates hypertension-induced renal damage, inflammation, and NF-κB activation. Braz J Med Biol Res 2018; 51(11): e7338.
[http://dx.doi.org/10.1590/1414-431x20187338] [PMID: 30183974]
[25]
Elewa H, Zalat ZA, Oriquat G, Rifaat R, El-Hadidy W, Yacoub S. Low-dose captopril and antioxidant combination as adjunct therapy in type-2 diabetic patients with coronary artery disease: A preliminary study. J Diabetolo 2011; 2(3): 2.
[26]
Kochi T, Shimizu M, Ohno T, et al. Preventive effects of the angiotensin-converting enzyme inhibitor, captopril, on the development of azoxymethane-induced colonic preneoplastic lesions in diabetic and hypertensive rats. Oncol Lett 2014; 8(1): 223-9.
[http://dx.doi.org/10.3892/ol.2014.2136] [PMID: 24959250]
[27]
Rohilla R, Goyal A, Varshney V, Semwal BC, Yadav HN. Role of Heme Oxygenase-1 (HO-1) and Endothelin-1 (ET-1) in modulation of cardioprotective effect of ischemic postconditioning in diabetic rat heart. Ind J Pharm Edu Res 2020; 54(3): 690-7.
[http://dx.doi.org/10.5530/ijper.54.3.119]
[28]
Gorąca A, Skibska B. Influence of ET-1 and ETA receptor blocker (BQ123) on the level of TNF-α in the brain rat. Pol Merkuriusz Lek 2016; 40(240): 369-71.
[PMID: 27403903]
[29]
Akbar DH, Hagras MM, Amin HA, Khorshid OA. Comparison between the effect of glibenclamide and captopril on experimentally induced diabetic nephropathy in rats. J Renin Angiotensin Aldosterone Syst 2013; 14(2): 103-15.
[http://dx.doi.org/10.1177/1470320312460881] [PMID: 23077081]
[30]
Tiwari AK, Goyal A, Semwal BC, Yadav HN. Effect of pravastatin on abrogated cardioprotective effect of late phase of preconditioning in hyperlipidaemic rats. Lat Am J Pharm 2019; 38(8): 1645-53.
[31]
Shakya R, Goyal A, Semwal BC, Singh NK, Yadav HN. Role of brain angiotensin (1-7) in chronic hyperglycaemia induced nephropathy in wistar rats. Ind J Pharma Edu Res 2017; 51(1): 83-91.
[http://dx.doi.org/10.5530/ijper.51.1.12]
[32]
Sinuani I, Averbukh Z, Gitelman I, et al. Mesangial cells initiate compensatory renal tubular hypertrophy via IL-10-induced TGF-beta secretion: Effect of the immunomodulator AS101 on this process. Am J Physiol Renal Physiol 2006; 291(2): F384-94.
[http://dx.doi.org/10.1152/ajprenal.00418.2005] [PMID: 16571592]
[33]
Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95(2): 351-8.
[http://dx.doi.org/10.1016/0003-2697(79)90738-3] [PMID: 36810]
[34]
Beutler E, Duron O, Kelly BM. Improved method for the determination of blood glutathione. J Lab Clin Med 1963; 61: 882-8.
[PMID: 13967893]
[35]
Lorkowska B, Bartus M, Franczyk M, et al. Hypercholesterolemia does not alter endothelial function in spontaneously hypertensive rats. J Pharmacol Exp Ther 2006; 317(3): 1019-26.
[http://dx.doi.org/10.1124/jpet.105.098798] [PMID: 16547168]
[36]
Trevisan R, Dodesini AR, Lepore G. Lipids and renal disease. J Am Soc Nephrol 2006; 17(4) (Suppl. 2): S145-7.
[http://dx.doi.org/10.1681/ASN.2005121320] [PMID: 16565240]
[37]
Currie G, McKay G, Delles C. Biomarkers in diabetic nephropathy: Present and future. World J Diabetes 2014; 5(6): 763-76.
[http://dx.doi.org/10.4239/wjd.v5.i6.763] [PMID: 25512779]
[38]
Reeves PG. Components of the AIN-93 diets as improvements in the AIN-76A diet. J Nutr 1997; 127(5) (Suppl.): 838S-41S.
[http://dx.doi.org/10.1093/jn/127.5.838S] [PMID: 9164249]
[39]
Dhaun N, Goddard J, Webb DJ. The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol 2006; 17(4): 943-55.
[http://dx.doi.org/10.1681/ASN.2005121256] [PMID: 16540557]
[40]
Remuzzi G, Bertani T. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 1990; 38(3): 384-94.
[http://dx.doi.org/10.1038/ki.1990.217] [PMID: 2232481]
[41]
Mather KJ, Lteif A, Steinberg HO, Baron AD. Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes. Diabetes 2004; 53(8): 2060-6.
[http://dx.doi.org/10.2337/diabetes.53.8.2060] [PMID: 15277386]
[42]
Spratt JC, Goddard J, Patel N, Strachan FE, Rankin AJ, Webb DJ. Systemic ETA receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men. Br J Pharmacol 2001; 134(3): 648-54.
[http://dx.doi.org/10.1038/sj.bjp.0704304] [PMID: 11588120]
[43]
Yanagisawa M, Inoue A, Ishikawa T, et al. Primary structure, synthesis, and biological activity of rat endothelin, an endothelium-derived vasoconstrictor peptide. Proc Natl Acad Sci 1988; 85(18): 6964-7.
[http://dx.doi.org/10.1073/pnas.85.18.6964] [PMID: 3045827]
[44]
Perfetto F, Tarquini R, Tapparini L, Tarquini B. Influence of non-insulin-dependent diabetes mellitus on plasma endothelin-1 levels in patients with advanced atherosclerosis. J Diabetes Complications 1998; 12(4): 187-92.
[http://dx.doi.org/10.1016/S1056-8727(97)00092-5] [PMID: 9647335]
[45]
Hafizi S, Wharton J, Chester AH, Yacoub MH. Profibrotic effects of endothelin-1 via the ETA receptor in cultured human cardiac fibroblasts. Cell Physiol Biochem 2004; 14(4-6): 285-92.
[http://dx.doi.org/10.1159/000080338] [PMID: 15319532]
[46]
Scheuer H, Gwinner W, Hohbach J, et al. Oxidant stress in hyperlipidemia-induced renal damage. Am J Physiol Renal Physiol 2000; 278(1): F63-74.
[http://dx.doi.org/10.1152/ajprenal.2000.278.1.F63] [PMID: 10644656]
[47]
Slater TF. Free-radical mechanisms in tissue injury. Biochem J 1984; 222(1): 1-15.
[http://dx.doi.org/10.1042/bj2220001] [PMID: 6383353]
[48]
Vahidirad M, Arab-Nozari M, Mohammadi H, Zamani E, Shaki F. Protective effect of captopril against diazinon induced nephrotoxicity and neurotoxicity via inhibition of ROS-NO pathway. Drug Chem Toxicol 2018; 41(3): 287-93.
[http://dx.doi.org/10.1080/01480545.2017.1391830] [PMID: 29115169]
[49]
Tan BL, Norhaizan ME, Liew WP, Sulaiman Rahman H. Antioxidant and oxidative stress: A mutual interplay in age-related diseases. Front Pharmacol 2018; 9: 1162.
[http://dx.doi.org/10.3389/fphar.2018.01162] [PMID: 30405405]
[50]
Noeman SA, Hamooda HE, Baalash AA. Biochemical study of oxidative stress markers in the liver, kidney and heart of high fat diet induced obesity in rats. Diabetol Metabol Synd 2011; 3(1): 1-8.
[51]
Mungunsukh O, George J, McCart EA, et al. Captopril reduces lung inflammation and accelerated senescence in response to thoracic radiation in mice. J Radiat Res 2021; 62(2): 236-48.
[http://dx.doi.org/10.1093/jrr/rraa142] [PMID: 33616187]
[52]
Chen Z, Zhang X, Lv S, et al. Treatment with endothelin-A receptor antagonist BQ123 attenuates acute inflammation in mice through T-cell-dependent polymorphonuclear myeloid-derived suppressor cell activation. Front Immunol 2021; 12: 641874.
[http://dx.doi.org/10.3389/fimmu.2021.641874] [PMID: 33828553]
[53]
Efrati S, Berman S, Hamad RA, et al. Effect of captopril treatment on recuperation from ischemia/reperfusion-induced acute renal injury. Nephrol Dial Transplant 2012; 27(1): 136-45.
[http://dx.doi.org/10.1093/ndt/gfr256] [PMID: 21680852]

Rights & Permissions Print Cite
Article Metrics
5
© 2025 Bentham Science Publishers | Privacy Policy